The effect offish oil on the course ofulcerative colitis was investigated in a randomised blinded controlied study. Eighty seven patients received supplements of 20 ml HiEPA fish oil as triglyceride (4.5 g of eicosapentaenoic acid) or olive oil placebo daily for one year. The oils were given in addition to standard drug therapy and trial entry was stratified for disease activity. Fish oil significantly increased the eicosapentaenoic acid content of rectal mucosa to 3.2% of total fatty acids at six months, compared with 0.63% for patients on olive oil. This was associated with increased synthesis of leukotriene B5, and 53% suppression of leukotriene B4 synthesis by ionophore -stimulated neutrophils. Leukotriene B4 suppression persisted for at least two months after treatment was stopped. Treatment with fish oil resulted in measurable, but only limited clinical benefit. For patients entering the trial in relapse (n=53), there was a significant reduction in corticosteroid requirement after one and two months treatment. There was a trend towards achieving remission (off corticosteroids) faster in the patients on fish oil, although differences were not significant. For patients in remission at trial entry or during the trial (n=69), there was no significant difference in the rate of relapse by log rank analysis. We conclude that fish oil supplementation produces a modest corticosteroid sparing effect in active disease, but there is no benefit in maintenance therapy.
Abstract
The effect offish oil on the course ofulcerative colitis was investigated in a randomised blinded controlied study. Eighty seven patients received supplements of 20 ml HiEPA fish oil as triglyceride (4.5 g of eicosapentaenoic acid) or olive oil placebo daily for one year. The oils were given in addition to standard drug therapy and trial entry was stratified for disease activity. Fish oil significantly increased the eicosapentaenoic acid content of rectal mucosa to 3.2% of total fatty acids at six months, compared with 0.63% for patients on olive oil. This was associated with increased synthesis of leukotriene B5, and 53% suppression of leukotriene B4 synthesis by ionophore -stimulated neutrophils. Leukotriene B4 suppression persisted for at least two months after treatment was stopped. Treatment with fish oil resulted in measurable, but only limited clinical benefit. For patients entering the trial in relapse (n=53), there was a significant reduction in corticosteroid requirement after one and two months treatment. There was a trend towards achieving remission (off corticosteroids) faster in the patients on fish oil, although differences were not significant. For patients in remission at trial entry or during the trial (n=69), there was no significant difference in the rate of relapse by log rank analysis. We conclude that fish oil supplementation produces a modest corticosteroid sparing effect in active disease, but there is no benefit in maintenance therapy.
In ulcerative colitis inflammation is characterised by marked influx and accumulation of neutrophils in the colonic mucosa. There is increasing evidence that leukotriene B4a may be pivotal in triggering or perpetuating this accumulation. It is a potent chemotactic factor' present in high levels in inflamed colonic mucosa2 where it may account for 80% of the lipid extractable chemotactic activity.' Treatments which reduce synthesis of leukotriene B4 may therefore be of benefit in ulcerative colitis.
Diets containing high levels of w-3 fatty acids, such as eicosapentaenoic acid and docosahexaenoic acid, are known to modify leukotriene production.45 Eicosapentaenoic acid levels in cell membranes rise, with an increase in eicosapentaenoic acid derived lipoxygenase products, such as leukotriene B56, which has markedly reduced chemotactic potency compared with leukotriene B4.7" In addition synthesis of lipoxygenase products derived from arachidonic acid is reduced as a result of diminished substrate release, 4 5- , p=0 44, Fig 1) .
Because those patients entering the trial in relapse generally had more active disease, compared with those patients entering in remission (as shown below), relapse rate of the subgroup of patients entering the trial in remission (19 on fish oil, 15 on olive oil), was also analysed separately. There was a trend for patients on fish oil to relapse later: 25% ofpatients takingfish oil relapsed by six months, compared with 40% for olive oil, but at one year the proportions were 42% for fish oil and 48% for olive oil (no significant difference, p=054).
Patients on fish oil tended to spend more time in remission than those on olive oil but the differences did not achieve statistical significance. For the total trial group, patients taking fish oil spent a median 230 days in remission compared with On an intention to treat analysis of all 96 patients, regarding all dropouts as treatment failures, the differences were again not significant.
Treatment ofrelapse
The median corticosteroid dosage at entry for patients in relapse was 10 mg for both fish oil and olive oil groups (Table IV) . Patients on fish oil had reduced corticosteroid requirements at one (5 mg) and two months (nil), compared with the olive oil group (8 mg at one month and 5 mg at two months, p=0-01, at both one and two months). The difference in corticosteroid consumption at one and two months remains equally significant when analysed on an intention to treat basis.
Analysing the time to achieve remission off corticosteroids by the log rank method (Fig 2) Oils were stopped in three subjects because of clinical events deemed possibly treatment related. One patient experienced pruritus after three months and treatment was withdrawn, and one patient with atopic eczema stopped treatment at six months because of worsening eczema (both on olive oil). One patient with chronic asthma normally controlled on salbutamol and beclomethasone inhalers, experienced worsening asthma at seven months, and oil was stopped (fish oil).
HAEMOSTASIS
At the end of the trial the time for bleeding to cease after mucosal biopsy was 25 (median, interquartile range 20-35) seconds for patient taking fish oil compared with 25 (20-40) seconds, for patients taking olive oil (not significant).
FATTY ACID LEVELS IN RECTAL MUCOSA
In patients taking fish oil, eicosapentaenoic acid levels rose significantly at all follow up visits (p<0-0001), Table V. Arachidonic acid levels were similar in the two groups at baseline, but at the end ofthe trial were significantly lower (6-8% versus 10.5%) in patients taking fish oil, compared with olive oil, p<0.01.
SYNTHESIS OF LIPOXYGENASE PRODUCTS BY IONOPHORE STIMULATED PERIPHERAL BLOOD NEUTROPHILS
Leukotriene BS Before entry into the trial there was no detectable synthesis of leukotriene B5 in any patient. All patients treated with fish oil synthesised detectable amounts of leukotriene B5 within two months, peaking at a median synthesis of 20 ng/ 107 neutrophils in response to 5 FtM A23187 by six months (Fig 3) , p=0-001 compared with baseline. These levels persisted throughout the trial but were undetectable two months after stopping fish oil. Patients treated with olive oil did not synthesise detectable amounts of leukotriene B5.
Leukotriene B4
Synthesis of leukotriene B4 at all concentrations of ionophore was significantly suppressed after two months treatment with fish oil and did not vary significantly thereafter. Thus, leukotriene B4 synthesis in response to ionophore 1-25 ,tM was suppressed by 49%, 53% and 59% compared with baseline after two, six, and 12 months treatment with fish oil (p<0-001), 
